ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Thanks 174ahc, according to Schafer, ANI is on course to achieve its short-term goal of generating $100 million of Ebitda.

Regarding corti drug, he expects them to file an sNDA [supplemental new drug application] this years (hoping it will be soon) to compete in this $1.5 billion Acthar market. The first 12 months ANI’s generic version is on the market, and he is not sure when that will be, ANI should generate $200 million in Ebitda.

So you are looking at over $300 million in Ebitda where ANI is guiding to between $59 - $63 Million in Ebitda for 2016.

Round table

Interview